Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2018-10-01 Capital/Financing Update
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
LSH Acquires Seng Vital for Cannabis Opportunities 2 pages 356.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 2 October 2018 about Lifespot Health completing the acquisition of Seng Vital and opening global opportunities with cannabis vaporiser technology. It focuses on the acquisition completion, product features, market potential, and future demonstrations. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a capital transaction (acquisition) and business update related to financing and company growth opportunities. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) because it announces the completion of an acquisition and discusses strategic business expansion related to capital assets.
2018-10-01 English
Lifespot Strengthens Go-To-Market Cannabis Strategy 3 pages 425.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 September 2018 regarding Lifespot Health Ltd's acquisition of the remaining 50% of Seng Vital, making it a 100% acquisition. The content focuses on the details of the acquisition, the strategic shift to commercialisation of cannabis vaporising technology, and future business plans. There are no financial statements, quarterly or annual results, or detailed financial performance data presented. The document is a corporate announcement about a capital transaction and strategic update rather than a financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 6408 characters, which is consistent with a detailed announcement but not a full report.
2018-09-17 English
Pause in trading 1 page 111.6KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It does not contain financial data, report content, or detailed information about financial performance or corporate actions. It is a regulatory announcement related to trading status, not a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2018-09-13 English
Trading Halt 2 pages 439.7KB
Regulatory Filings Classification · 95% confidence The document is a market announcement regarding a trading halt requested by Lifespot Health Limited pending an announcement related to an acquisition. It references ASX Listing Rule 17.1 and states the halt is until the announcement is released. There is no actual financial data, report content, or detailed announcement included, only a procedural notice about the trading halt. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain a full report or detailed financial information.
2018-09-13 English
Appointment of Greg Plunkett as Non-Executive Director 2 pages 120.5KB
Board/Management Information Classification · 100% confidence The document is an announcement dated 11 Sept 2018 regarding the appointment of Greg Plunkett as a Non-Executive Director of Lifespot Health Ltd. It details his background, qualifications, and the strategic value he brings to the board. There is no financial data, no mention of a report or filing, and the content focuses solely on a change in the company's board of directors. This fits the definition of Board/Management Information (MANG). The document length is short and it is clearly an announcement, not a report or transcript.
2018-09-10 English
Initial Director's Interest Notice 2 pages 58.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1, which pertains to disclosures of directors' interests in securities. The content details the director's relevant interests in securities and contracts, with no financial data or report content. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions or interests by company directors. The document length is short and focused solely on director interests, confirming it is not a full financial report or announcement of a report. Therefore, the correct classification is DIRS (Director's Dealing).
2018-09-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.